Pancreatic cancer is a challenging disease due to resistance to a range of anticancer agents and immunotherapies. To uncover new treatment options, preclinical models need to better recapitulate human disease, including the tumor microenvironment (TME) which contributes to drug resistance. Cutting-edge immuno-oncology technologies also need to be explored.
This White Paper presents orthotopic tumor homografts as a clinically-relevant pancreatic cancer preclinical model, which more accurately replicates the TME in vivo. These immunocompetent models allow advanced assessment of novel agents targeting the disease, including immunotherapies.
CAR-T cell therapy for pancreatic cancer is also discussed as a novel treatment modality. Discover how patient-derived xenografts (PDX) recapitulating human mesothelin expression levels are used to assess anti-MSLN CAR-T cell therapy efficacy.